Onderneming Stemline Therapeutics, Inc.
Aandelen
US85858C1071
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 08-08-03 |
David Gionco
DFI | Director of Finance/CFO | 63 | 16-01-14 |
Jeffrey Levitt
CMP | Compliance Officer | - | 01-03-18 |
Nassir Habboubi
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Kenneth Hoberman
COO | Chief Operating Officer | 59 | 01-01-13 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 08-08-03 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 52 510 785 | 52 125 679 ( 99,27 %) | 0 | 99,27 % |
Bedrijfsgegevens
Stemline Therapeutics, Inc.
750 Lexington Avenue 11th floor
10022, New York
+646-502-2310
http://www.stemline.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |